ES2237963T3 - Inhibidores de farnesil proteina transferasa. - Google Patents

Inhibidores de farnesil proteina transferasa.

Info

Publication number
ES2237963T3
ES2237963T3 ES99967139T ES99967139T ES2237963T3 ES 2237963 T3 ES2237963 T3 ES 2237963T3 ES 99967139 T ES99967139 T ES 99967139T ES 99967139 T ES99967139 T ES 99967139T ES 2237963 T3 ES2237963 T3 ES 2237963T3
Authority
ES
Spain
Prior art keywords
alkyl
aryl
halo
represent
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99967139T
Other languages
English (en)
Spanish (es)
Inventor
Timothy Guzi
Dinanath F. Rane
Alan K. Mallams
Alan B. Cooper
Ronald J. Doll
Viyyoor M. Girijavallabhan
Arthur G. Taveras
Corey Strickland
Joseph M. Kelly
Jianping Chao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2237963T3 publication Critical patent/ES2237963T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES99967139T 1998-12-18 1999-12-16 Inhibidores de farnesil proteina transferasa. Expired - Lifetime ES2237963T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21656098A 1998-12-18 1998-12-18
US216560 1998-12-18

Publications (1)

Publication Number Publication Date
ES2237963T3 true ES2237963T3 (es) 2005-08-01

Family

ID=22807539

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99967139T Expired - Lifetime ES2237963T3 (es) 1998-12-18 1999-12-16 Inhibidores de farnesil proteina transferasa.

Country Status (23)

Country Link
EP (1) EP1140904B1 (enExample)
JP (1) JP2002533335A (enExample)
KR (1) KR20010081115A (enExample)
CN (1) CN1285588C (enExample)
AR (1) AR021716A1 (enExample)
AT (1) ATE293622T1 (enExample)
AU (1) AU2347900A (enExample)
BR (1) BR9916328A (enExample)
CA (1) CA2354774C (enExample)
CO (1) CO5160344A1 (enExample)
CZ (1) CZ20011900A3 (enExample)
DE (1) DE69924876T2 (enExample)
ES (1) ES2237963T3 (enExample)
HU (1) HUP0203054A3 (enExample)
ID (1) ID29065A (enExample)
IL (1) IL143409A0 (enExample)
NO (1) NO20012960L (enExample)
PE (1) PE20001516A1 (enExample)
PL (1) PL348294A1 (enExample)
SK (1) SK7582001A3 (enExample)
TR (1) TR200101754T2 (enExample)
WO (1) WO2000037458A1 (enExample)
ZA (1) ZA200104236B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL149544A0 (en) * 1999-11-10 2002-11-10 Aventis Pharma Gmbh N-ACYLPYRROLIDIN-2-YLALKYLBENZAMIDINE DERIVATIVES AS INHIBITORS OF FACTOR Xa
US7361663B2 (en) 1999-11-10 2008-04-22 Aventis Pharmaceuticals Inc. N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor Xa
US6589978B2 (en) 2000-06-30 2003-07-08 Hoffman-La Roche Inc. 1-sulfonyl pyrrolidine derivatives
AR033680A1 (es) * 2000-08-30 2004-01-07 Schering Corp Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
US6376514B1 (en) 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
US6809093B2 (en) 2000-10-17 2004-10-26 H. Lee Moffitt Cancer & Research Institute, Inc. 2-substituted heterocyclic compounds
AU2002236813A1 (en) 2001-01-22 2002-07-30 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
ATE455108T1 (de) 2001-02-16 2010-01-15 Aventis Pharma Inc Heterocyclische substituierte carbonyl derivate und ihre verwendung als dopamin d3 rezeptor liganden
WO2002080895A2 (en) * 2001-04-06 2002-10-17 Schering Corporation Treatment of malaria with farsenyl protein transferase inhibitors
FR2825705B1 (fr) * 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
GB0115862D0 (en) * 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
US6740757B2 (en) * 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2844273B1 (fr) 2002-09-05 2008-04-04 Aventis Pharma Sa Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
AU2003293555A1 (en) * 2002-12-17 2004-07-29 Schering Corporation 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
CN101115486A (zh) * 2004-12-13 2008-01-30 先灵公司 新的法呢基蛋白转移酶抑制剂及其治疗癌症的用途
CN101128202A (zh) 2004-12-14 2008-02-20 先灵公司 法呢基蛋白质转移酶抑制剂和用于治疗增殖性疾病的方法
WO2007084498A1 (en) * 2006-01-19 2007-07-26 Schering Corporation Piperazine derivatives as farnesyl protein transferase inhibitors
AU2009249306B8 (en) * 2008-05-22 2013-07-25 Merck Canada Inc. Process for the preparation of an orexin receptor antagonist
HU231150B1 (hu) 2017-03-13 2021-03-29 Richter Gedeon Nyrt Eljárás racém 3-alkilpiperidin-3-karbonsav-etil-észterek optikai izomerjeinek elválasztására
JP2022534704A (ja) 2019-06-04 2022-08-03 ヘイガー バイオサイエンシズ,エルエルシー オレキシンアンタゴニストとしてのイミダゾロ誘導体、組成物、及び方法
TWI907472B (zh) 2020-08-05 2025-12-11 匈牙利商羅特格登公司 具藥理活性之經雜環取代的吡唑并〔1,5-a〕嘧啶衍生物
CN114349711B (zh) * 2022-02-28 2023-08-15 四川依维欣医药科技有限公司 一种(R)-1-Boc-3-羟甲基哌嗪的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111235A (en) * 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
GB9420172D0 (en) * 1994-10-06 1994-11-23 Boots Co Plc Therapeutic agents
IL117798A (en) * 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
ATE273299T1 (de) * 1997-06-17 2004-08-15 Schering Corp Benzpyrido cycloheptan derivate mit farnesyl protein transferase inhibierender wirkung

Also Published As

Publication number Publication date
NO20012960L (no) 2001-08-15
PL348294A1 (en) 2002-05-20
PE20001516A1 (es) 2001-01-06
ZA200104236B (en) 2002-08-23
EP1140904A1 (en) 2001-10-10
SK7582001A3 (en) 2002-03-05
HK1036279A1 (en) 2001-12-28
CZ20011900A3 (cs) 2002-02-13
WO2000037458A1 (en) 2000-06-29
BR9916328A (pt) 2001-10-02
CA2354774C (en) 2009-05-26
AR021716A1 (es) 2002-07-31
ID29065A (id) 2001-07-26
NO20012960D0 (no) 2001-06-15
ATE293622T1 (de) 2005-05-15
AU2347900A (en) 2000-07-12
DE69924876T2 (de) 2006-03-02
DE69924876D1 (de) 2005-05-25
HUP0203054A3 (en) 2004-01-28
CO5160344A1 (es) 2002-05-30
IL143409A0 (en) 2002-04-21
TR200101754T2 (tr) 2002-05-21
CN1285588C (zh) 2006-11-22
HUP0203054A2 (hu) 2003-01-28
CN1352642A (zh) 2002-06-05
KR20010081115A (ko) 2001-08-27
CA2354774A1 (en) 2000-06-29
EP1140904B1 (en) 2005-04-20
JP2002533335A (ja) 2002-10-08

Similar Documents

Publication Publication Date Title
CO5160344A1 (es) Inhibidores de transferasa de proteina farnesilo
CO5721002A2 (es) Derivados de acido 3-(4-benciloxifenil) propanoico
DK0586471T3 (da) Perhydroisoindolderivater og deres fremstilling
ECSP034611A (es) Aminotiazoles y su uso como antagonistas del receptor de adenosina
SE7601205L (sv) Derivat av omettade aminosyror
CO5540302A2 (es) Heteroarilos multiciclicos con quinuclidinas para el tratamiento de enfermedades
PE20051057A1 (es) Fenilalanina-amidas sustituidas por heteroaroilo
AR048567A1 (es) Derivados de benzoxazinona, su preparacion y composiciones farmaceuticas.
AR035548A1 (es) Compuestos organicos
CO4950561A1 (es) Derivados de ergolina
CO5550437A2 (es) Compuestos quimicos
TW200722433A (en) Phosphorus compounds, use thereof and flame retarding polyester fibers
CO5160350A1 (es) Inhibidores de transferasa de proteina farnesilo
GB1077276A (en) Novel thiaza heterocyclics
SE7607088L (sv) 5-fluor-uracilderivat.
CO4761067A1 (es) Nuevas heteroalioxazolidinonas
PE20242281A1 (es) Novedosos compuestos de piridina carboxamida biciclica sustituida fusionada para combatir hongos fitopatogenicos
ES2118954T3 (es) Nuevos derivados perhidroisoindol y su preparacion.
CO4890850A1 (es) Derivados de 6-pirrolidin-2-ilpiridinas, su reparacion y preparacion en terapeutica.
AR007690A1 (es) Sales de complejos anionicos de ru (iii) como agentes antimetastasicos y antineoplasicos, procedimiento para la preparacion y usos de dichas sales, y composiciones farmaceuticas que las contienen.
ES476256A1 (es) Un procedimiento para preparar un derivado azoico
CO4810380A1 (es) Derivados de eritromicina
SE7704246L (sv) Desinfektionsmedel
DK439384D0 (da) Derivater af 4-(3-alkynyloxy-2-hydroxypropyl)-piperazin-1-yl-n-phenylacetamid, fremgangsmaade til fremstilling deraf samt farmaceutisk middel indeholdende disse
DE69002275D1 (de) Stabilisierung von organischen verbindungen.